Bio-Techne Corporation (TECH)

Bio-Techne's stock has experienced a decline in the past six months and has underperformed the S&P 500 Index. Key events impacting the stock price include Q2 2025 earnings where shares surged after surpassing forecasts, analyst downgrades from Baird and Keybanc, Q3 2025 earnings where the stock dipped slightly post-earnings despite beating EPS forecasts, and Q4 and Fiscal 2024 earnings where shares plunged after missing revenue estimates.

Bio-Techne believes there is some seasonality in demand for its products, partly attributed to vacation patterns, though specific details were not provided.

Bio-Techne Corporation is a global life sciences company specializing in the development, manufacture, and sale of reagents, analytical instruments, and precision diagnostics. The company operates within the healthcare sector, specifically in the biotechnology and drugs industry, and is also categorized under medical equipment. Bio-Techne's catalog includes over 500,000 products and services, structured across three primary segments: Protein Sciences, Diagnostics and Genomics, and Spatial Biology. The company also conducts research in areas such as cancer, cardiovascular, cell and gene therapy, COVID-19, and regenerative medicine.

Bio-Techne is headquartered in Minneapolis, Minnesota, and employs over 3,000 people globally across 34 locations. The company has a global presence with operations and distribution networks in North America, Europe, and Asia, including direct sales offices and a distributor network covering emerging markets. They have also established R&D Systems China Co., Ltd. in Shanghai, China, and R&D Systems Hong Kong Limited. Europe has shown strong growth.

Bio-Techne has a reputation for high product quality and aims to be the standard for biological content in the research market through continued innovation. Failure to comply with privacy and security laws could result in fines, penalties, and damage to its reputation, a risk elevated by recent acquisitions.

Bio-Techne Corporation's stock ownership is primarily held by institutional investors, who hold approximately 93.48% or 69.20% of the company's stock. Insiders own approximately 0.23% of the stock. Public companies and individual investors hold approximately 6.29% or 24.28% of the stock.